PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Orforglipron

LY3502970; OWL833

Classification: Oral non-peptide GLP-1 agonist

Mechanism: Small-molecule GLP-1 receptor agonist; orally bioavailable

Benefits: Weight loss ~14-15% Phase 2; oral; glycemic control

Evidence tier: Phase 3 · Availability: Investigational

Primary sources

  1. Wharton S et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 2023. PMID 37351564

Loading interactive view…